Executive Summary Overview Eosinophilic Esophagitis History Symptoms Diagnosis Pathophysiology Genetics of Eosinophilic Esophagitis Treatment Emerging therapies for Eosinophilic Esophagitis Pipeline Therapeutics Comparative Analysis Late Stage Products (Phase III) Comparative Analysis SHP621: Shire Product Description Research and Development Product Development Activities (The list continues) Mid-Stage Products (Phase II) Comparative Analysis Pre-Clinical Products Comparative Analysis Therapeutic Assessment: Active Products Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant Products Comparative Analysis Appendix

Table 1: Total Products for Eosinophilic Esophagitis Table 2: Late Stage Products (Phase III) Table 3: Mid Stage Products (Phase II) Table 4: Pre-clinical Products Table 5: Assessment by Route of Administration Table 6: Assessment by Stage and Route of Administration Table 7: Assessment by Molecule Type Table 8: Assessment by Stage and Molecule Type Table 9: Dormant Products Figure 1: Esophagus affected by Eosinophilic Esophagitis Figure 2: Endoscopy image showing rings, linear and narrow caliber Figure 3: Pathogenesis of Eosinophilic Esophagitis Figure 4: Total Products for Eosinophilic Esophagitis Figure 5: Late Stage Products (Phase III) Figure 6: Mid Stage Products (Phase II) Figure 7: Pre-clinical Products Figure 8: Assessment by Route of Administration Figure 9: Assessment by Stage and Route of Administration Figure 10: Assessment by Molecule Type Figure 11: Assessment by Stage and Molecule Type Figure 12: Dormant Products

Adare Pharmaceuticals Atopix Therapeutics Biotica Pharmaceuticals Calypso Biotech Celgene DBV Technologies GlaxoSmithKline Novartis Quorum Innovations Sanofi/Regeneron Shire Teva